RNS Number : 3669N


29 January 2021


("IXICO" or the "Company")

PDMR Dealing

Issue of Equity on exercise of options

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience , announces that it has made an application to the London Stock Exchange for the admission to trading on AIM of 156,471 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options by the VP Alliance Management (PDMR).

The New Shares are expected to be admitted to trading on AIM on 5 February 2021.

Total voting rights

Application has been made for admission to trading on AIM of 156,471 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00 a.m. on 5 February 2021, following which there will be in total 47,292,939 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

T he below makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

Details of PDMR transaction

 1     Details of the person discharging managerial responsibilities 
        / person closely associated 
 a)    Name                               Sylke Grootoonk 
      ---------------------------------  -------------------------------------- 
 2     Reason for the notification 
 a)    Position/status                    PDMR (VP Alliance Management) 
      ---------------------------------  -------------------------------------- 
 b)    Initial notification               Initial notification 
      ---------------------------------  -------------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
 a)    Name                               IXICO plc 
      ---------------------------------  -------------------------------------- 
 b)    LEI                                2138005M1F59O6HWSA97 
      ---------------------------------  -------------------------------------- 
 4     Details of the transaction(s): section to be repeated 
        for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
 a)    Description of the                 Ordinary Shares in IXICO plc 
        financial instrument, 
        type of instrument 
       Identification code                GB00BCLY7L40 
 b)    Nature of the transaction          Exercise of options 
      ---------------------------------  -------------------------------------- 
 c)    Price(s) and volume(s) 
                                          ---------------------  ------------ 
                                           Exercise Price(s)      Volume(s) 
                                          ---------------------  ------------ 
                                           30.5p                  112,942 
                                          ---------------------  ------------ 
                                           34.0p                  43,529 
                                          ---------------------  ------------ 
 d)    Aggregated information 
  - Aggregated volume                1 56,471 shares 
  - Price                            31.5p 
 e)    Date of the transaction            5 Feburary 2021 
      ---------------------------------  -------------------------------------- 
 f)    Place of the transaction           N/A 
      ---------------------------------  -------------------------------------- 

For further information please contact:

 IXICO plc                                      +44 (0)20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                              +44 (0)20 7397 8900 
 Giles Balleny / Max Gould (Corporate 
 Michael F Johnson / Russell Kerr 
 Walbrook PR Ltd                                +44 (0)20 7933 8780 
 Paul McManus / Lianne Cawthorne               IXICO@walbrookpr.com 
 Alice Woodings 


IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

   More information is available on www.IXICO.com   and follow us on Twitter @IxicOplc 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 29, 2021 05:19 ET (10:19 GMT)